Evidence map›Paper›PMID 38978071›Full record

ArticleBreast cancer research : BCR2024

Stromal lymphocytes are associated with upgrade of B3 breast lesions.

Tanjina Kader, Elena Provenzano, Madawa W Jayawardana, Shona Hendry, Jia-Min Pang, Kenneth Elder, David J Byrne, Lauren Tjoeka, Helen Ml Frazer, Eloise House and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Tanjina KaderPeter MacCallum Cancer Centre, 305 Grattan St, Melbourne, 3000, Australia.
Elena ProvenzanoDepartment of Histopathology, Addenbrookes Hospital, and Cambridge NIH Biomedical Research Centre, Cambridge, UK.
Madawa W JayawardanaPeter MacCallum Cancer Centre, 305 Grattan St, Melbourne, 3000, Australia.
Shona HendryDepartment of Anatomical Pathology, St Vincent's Hospital, Fitzroy, Australia.
Jia-Min PangPeter MacCallum Cancer Centre, 305 Grattan St, Melbourne, 3000, Australia.
Kenneth ElderThe Breast Service, The Royal Women's Hospital, Melbourne, Australia.
David J ByrnePeter MacCallum Cancer Centre, 305 Grattan St, Melbourne, 3000, Australia.
Lauren TjoekaPeter MacCallum Cancer Centre, 305 Grattan St, Melbourne, 3000, Australia.
Helen Ml FrazerSt Vincent's Breast Screen, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia.
Eloise HouseDepartment of Anatomical Pathology, St Vincent's Hospital, Fitzroy, Australia.
Sureshni I JayasingheDepartment of Anatomical Pathology, St Vincent's Hospital, Fitzroy, Australia.
Holly KeanePeter MacCallum Cancer Centre, 305 Grattan St, Melbourne, 3000, Australia.
Anand MurugasuThe Breast Service, The Royal Women's Hospital, Melbourne, Australia.
Neeha RajanThe Breast Service, The Royal Women's Hospital, Melbourne, Australia.
Islam M MiligyNottingham Breast Cancer Research Centre, Academic Unit for Translational Medical Sciences, School of Medicine, Biodiscovery Institute, Department of Histopathology, University of Nottingham, Nottingham University Hospitals NHS Trust, City Hospital, Nottingham, UK.
Michael TossNottingham Breast Cancer Research Centre, Academic Unit for Translational Medical Sciences, School of Medicine, Biodiscovery Institute, Department of Histopathology, University of Nottingham, Nottingham University Hospitals NHS Trust, City Hospital, Nottingham, UK.
Andrew R GreenNottingham Breast Cancer Research Centre, Academic Unit for Translational Medical Sciences, School of Medicine, Biodiscovery Institute, Department of Histopathology, University of Nottingham, Nottingham University Hospitals NHS Trust, City Hospital, Nottingham, UK.
Emad A RakhaNottingham Breast Cancer Research Centre, Academic Unit for Translational Medical Sciences, School of Medicine, Biodiscovery Institute, Department of Histopathology, University of Nottingham, Nottingham University Hospitals NHS Trust, City Hospital, Nottingham, UK.
Stephen B FoxPeter MacCallum Cancer Centre, 305 Grattan St, Melbourne, 3000, Australia.
G Bruce MannThe Royal Melbourne Hospital, Melbourne, Australia.
Ian G CampbellPeter MacCallum Cancer Centre, 305 Grattan St, Melbourne, 3000, Australia.
Kylie L GorringePeter MacCallum Cancer Centre, 305 Grattan St, Melbourne, 3000, Australia. kylie.gorringe@petermac.org.

Funding

Cancer Australia 2002944National Breast Cancer Foundation 2002944National Health and Medical Research Council 1063092National Health and Medical Research Council 1193630
6 · The paper itself

Abstract

Various histopathological, clinical and imaging parameters have been evaluated to identify a subset of women diagnosed with lesions with uncertain malignant potential (B3 or BIRADS 3/4A lesions) who could safely be observed rather than being treated with surgical excision, with little impact on clinical practice. The primary reason for surgery is to rule out an upgrade to either ductal carcinoma in situ or invasive breast cancer, which occurs in up to 30% of patients. We hypothesised that the stromal immune microenvironment could indicate the presence of carcinoma associated with a ductal B3 lesion and that this could be detected in biopsies by counting lymphocytes as a predictive biomarker for upgrade. A higher number of lymphocytes in the surrounding specialised stroma was observed in upgraded ductal and papillary B3 lesions than non-upgraded (p < 0.01, negative binomial model, n = 307). We developed a model using lymphocytes combined with age and the type of lesion, which was predictive of upgrade with an area under the curve of 0.82 [95% confidence interval 0.77-0.87]. The model can identify some patients at risk of upgrade with high sensitivity, but with limited specificity. Assessing the tumour microenvironment including stromal lymphocytes may contribute to reducing unnecessary surgeries in the clinic, but additional predictive features are needed.

Indexed as

Breast NeoplasmsLymphocytesStromal CellsTumor MicroenvironmentAdultAgedBiomarkers, TumorCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingFemaleHumansLymphocytes, Tumor-InfiltratingMiddle AgedNeoplasm GradingBiomarkers, TumorAtypical ductal hyperplasiaB3 lesionsBiomarkerDuctal carcinoma in situEarly breast neoplasiaLesions of uncertain malignant potentialStromal lymphocytesTumour infiltrating lymphocytesUpgrade

Identifiers

PMID38978071
PMCPMC11232297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.